ZYN Nicotine Pouches Short in Supply in U.S. Due to Sales Surge

Market by 2FIRSTS.ai
May.20.2024
ZYN Nicotine Pouches Short in Supply in U.S. Due to Sales Surge
ZYN nicotine pouches may be hard to find in states like New York, New Jersey, and Florida, as demand rises.

According to a report by Bloomberg on May 20th, the popular nicotine pouch brand ZYN, owned by PMI, may become harder to find in several states, including New York, New Jersey, and Florida.

 

Some tobacco shops in New York have revealed that the nicotine pouches costing around $5 retail price have sold out. Wholesalers in New Jersey and Florida have also reported difficulties in stocking ZYN. It is said that this shortage has been ongoing for several weeks. During the April earnings conference call, the company's CFO Emmanuel Babeau stated that the growth of ZYN has "undoubtedly brought some tension to the supply chain."

 

In February of this year, PMI company reported that sales of ZYN in the United States are expected to reach nearly 385 million cans by 2023, a 62% increase compared to the previous year. The company predicts that business performance in 2024 will be even better, with sales in the US expected to reach 520 million cans this year. As global tobacco consumption continues to decline, the company has been pushing to create more smoke-free products.

 

In April 2024, the Food and Drug Administration (FDA) issued warning letters to retailers selling ZYN nicotine pouches to minors and filed civil penalty complaints. The agency stated that it had sent 119 warning letters to retailers from October 2023 to February 2024 and filed 41 civil lawsuits.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Opens 2026 National E-Cigarette Standards Project for Public Submissions
China Opens 2026 National E-Cigarette Standards Project for Public Submissions
The State Administration for Market Regulation (SAMR) and the State Tobacco Monopoly Administration (STMA) jointly announced the launch of the 2026 National Standardization Project for E-cigarettes. The initiative, coordinated by the National Technical Committee on Standardization of E-cigarettes, aims to enhance the industry’s regulatory framework through new standards on manufacturing, storage, distribution, and evaluation.
Nov.27 by 2FIRSTS.ai
PMI Japan to Launch Limited Edition IQOS ILUMA i "Galaxy Blue", Introduces New TEREA Clear Regular Flavo
PMI Japan to Launch Limited Edition IQOS ILUMA i "Galaxy Blue", Introduces New TEREA Clear Regular Flavo
PMI Japan unveils limited edition IQOS ILUMA i in Galaxy Blue, inspired by the universe, set to launch on October 29.
Oct.14 by 2FIRSTS.ai
PMI Launches New ZYN Nicotine Pouch in the Philippines, Available Simultaneously at IQOS Stores and on the Official Website
PMI Launches New ZYN Nicotine Pouch in the Philippines, Available Simultaneously at IQOS Stores and on the Official Website
PMI’s Philippine affiliate, PMFTC, has launched the new ZYN Bright Green 1.5 mg nicotine pouch in Manila with refreshed packaging, calling it the latest step in the company’s “smoke-free” transition initiated in 2016. The product will be available starting in November at IQOS stores across Metro Manila and on the official website.
Nov.10 by 2FIRSTS.ai
Spain to Tighten E-Cigarette Regulation: Public-Place Ban, Advertising Limits, Flavour Controls
Spain to Tighten E-Cigarette Regulation: Public-Place Ban, Advertising Limits, Flavour Controls
Spain is advancing a 2025 Anti-Tobacco Law to align e-cigs with tobacco, tighten public-use/advertising/flavour rules, study phasing out disposables; cannabinoid, nicotine-free vapes are rising.
Oct.21 by 2FIRSTS.ai
Product | Featuring an ultra-thin metal body and a “Champagne Gold” design, Sikary launches the Sikary Fit in the Middle East
Product | Featuring an ultra-thin metal body and a “Champagne Gold” design, Sikary launches the Sikary Fit in the Middle East
Sikary has listed its new disposable “Fit” on the official site and UAE channels. The device features a 13 mm metal body with a 12 mL e-liquid chamber and is advertised for up to 12,000 puffs, priced at around AED 35 per unit.
Oct.28 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai